Akrish Sharon, Ben-Izhak Ofer, Sabo Edmond, Rachmiel Adi
Rambam Medical Center, Department of Oral and Maxillofacial Surgery, Bat Galim, Haifa, Israel; Rambam Medical Center, Department of Pathology, Bat Galim, Haifa, Israel; Technion School of Medicine, Bat Galim, Haifa, Israel.
Rambam Medical Center, Department of Pathology, Bat Galim, Haifa, Israel; Technion School of Medicine, Bat Galim, Haifa, Israel.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Mar;119(3):318-25. doi: 10.1016/j.oooo.2014.10.023. Epub 2014 Nov 7.
Proliferative verrucous leukoplakia (PVL), a potentially malignant disorder, often undergoes malignant transformation to oral squamous cell carcinoma. The aim of our study was to document and compare the histologic, immunohistochemical, and clinical features and the survival rates of carcinoma arising in patients with PVL (p-scca) with conventional squamous cell carcinoma (c-scca) in order to determine if p-scca should be categorized as a separate clinical entity.
A retrospective review of 11 patients with PVL, 38 with p-scca tumors and 49 with c-scca tumors: buccal mucosa (n = 28) and gingiva or palate (n = 21). Immunohistochemistry was performed by using antibodies directed against p16, p53, and ki67.
P-scca had lower clinical stage (P = .0001), smaller tumor size (P = .0033), no lymph node metastasis (P = .0002) or distant metastasis (P = .05), and better short term (P = .03), but not long term (P = .12) survival. Microscopically, p-scca tumor thickness was significantly less (P = .0001). P-53 overexpression was more common in p-scca (P = .0043) but not ki67 or p16 overexpression.
P-scca, compared with c-scca, presented with significantly better prognostic factors and short-term survival rates and longer duration of disease. Our results suggest that p-scca may represent a distinct entity, which may have practical implications when deciding on treatment. Further studies on a larger cohort of patients are recommended.
增殖性疣状白斑(PVL)是一种潜在的恶性疾病,常发生恶性转化为口腔鳞状细胞癌。我们研究的目的是记录和比较PVL患者发生的癌(p-scca)与传统鳞状细胞癌(c-scca)的组织学、免疫组化和临床特征以及生存率,以确定p-scca是否应归类为一个单独的临床实体。
回顾性分析11例PVL患者、38例p-scca肿瘤患者和49例c-scca肿瘤患者:颊黏膜(n = 28)和牙龈或腭部(n = 21)。采用针对p16、p53和ki67的抗体进行免疫组化。
p-scca临床分期较低(P = .0001),肿瘤尺寸较小(P = .0033),无淋巴结转移(P = .0002)或远处转移(P = .05),短期生存率较好(P = .03),但长期生存率无差异(P = .12)。显微镜下,p-scca肿瘤厚度明显更薄(P = .0001)。p53过表达在p-scca中更常见(P = .0043),但ki67或p16过表达无差异。
与c-scca相比,p-scca具有明显更好的预后因素、短期生存率和更长的疾病持续时间。我们的结果表明,p-scca可能代表一种独特的实体,这在决定治疗方案时可能具有实际意义。建议对更大队列的患者进行进一步研究。